Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) ...

Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

Caption: Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said she believed the 'greatest good' right now can be achieved by allowing some Americans who are ...

Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were "substantially higher" in people who got its new bivalent booster compared with people who received ...

NEW YORK and MAINZ, GERMANY, November 4, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (BNTX) (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust ...

Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) is FDA-authorized under Emergency Use Authorization (EUA) for use in individuals 12 years of age and older as a single ...

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines ...

(Reuters) – Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are ...

BioNTech reported EUR 6.1 billion in revenue and EUR 3.2 billion in net profit in the third quarter, driven by BioNTech and partner Pfizer's sales of COVID-19 vaccine Comirnaty, and we're maintaining ...

The US Food and Drug Administration on Thursday authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17. It's the first Covid-19 vaccine booster authorized for ...